Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Sept. 7, 2011 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:
DND), announced today that Larry Andrews, President and Chief Executive
Officer, is presenting at the Rodman & Renshaw Annual Global
Investment Conference, which is being held in New York City from
September 11-13 at the Waldorf Astoria. Mr. Andrews will provide an
update on the Company's drug development activities and plans. Cipher's
presentation will take place on Monday, September 12, 2011 at 4:30 pm
ET in the Metropolitan East room.
Cipher's presentation will be available at www.cipherpharma.com.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a commercial-stage drug development company
focused on commercializing novel formulations of successful, currently
marketed molecules using advanced drug delivery technologies. Cipher's
strategy is to in-license products that incorporate proven drug
delivery technologies and advance them through the clinical development
and regulatory approval stages, after which the products are
out-licensed to international partners. Because Cipher's products are
based on proven technology platforms applied to currently marketed
drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. The
Company's lead compound is being marketed in the United States by Kowa
Pharmaceuticals America under the label Lipofen®. Cipher's second
product, an extended-release version of the pain reliever tramadol, has
received final FDA approval and is expected to be launched by Vertical
Pharmaceuticals in the United States in Q3 2011. The Company's third
product, a novel formulation of the acne treatment isotretinoin,
recently completed its final Phase III safety study.
Cipher is listed on the Toronto Stock Exchange under the symbol 'DND'
and has approximately 24 million shares outstanding. For more
information, please visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information: